Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pemphigus: a treatment update.

Sarah E Dick1, Victoria P Werth

  • 1Department of Dermatology, Philadelphia VA Medical Center, University of Pennsylvania, Philadelphia, PA, USA.

Autoimmunity
|November 15, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effects of CB2R Activation on Inflammatory Pathways in Dermatomyositis.

Biomedicines·2026
Same author

Prednisone dosage is the primary modifiable risk factor for infection in pemphigus with rituximab treatment: A retrospective analysis of 105 patients.

Journal of the American Academy of Dermatology·2026
Same author

Rapid Onset of Response in Adults with Dermatomyositis Receiving Dazukibart: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study.

Clinical, cosmetic and investigational dermatology·2026
Same author

Plasmacytoid dendritic cells in systemic and cutaneous lupus erythematosus: an evolving understanding.

Frontiers in immunology·2026
Same author

Evaluation of the applicability of the Cutaneous Lupus Erythematosus Area and Severity Index in Filipino cutaneous lupus erythematosus patients.

JAAD international·2026
Same author

Reply.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same journal

Platycodin D attenuates proliferation, migration, and angiogenesis in RA-stimulated endothelial cells via CD146 modulation.

Autoimmunity·2026
Same journal

CCDC77 and SLC45A3 mediate the genetic mechanism of Hashimoto's thyroiditis through IL-6.

Autoimmunity·2026
Same journal

Multi-cohort transcriptomic analysis with machine learning identifies interferon-related candidate genes in systemic lupus erythematosus.

Autoimmunity·2026
Same journal

IgA Vasculitis with necrotizing arteritis: a multicenter retrospective study from the French Vasculitis Study Group and systematic review of the literature.

Autoimmunity·2026
Same journal

Global research trends in ferroptosis in autoimmune diseases: a bibliometric and visual analysis (2018-2025).

Autoimmunity·2026
Same journal

Monocyte exhaustion associated with systemic lupus erythematosus.

Autoimmunity·2026
See all related articles

Pemphigus management focuses on remission with minimal side effects, as treatment complications, not the disease itself, cause harm. Research is advancing, but more controlled studies are needed to confirm treatment effectiveness.

Area of Science:

  • Autoimmune diseases
  • Dermatology
  • Immunology

Background:

  • Pemphigus encompasses rare autoimmune mucocutaneous blistering diseases.
  • Key subtypes include pemphigus vulgaris (PV) and pemphigus foliaceus (PF).
  • Significant morbidity and mortality were historically associated with pemphigus.

Purpose of the Study:

  • To review current and novel therapeutic strategies for pemphigus.
  • To evaluate the evidence supporting existing pemphigus treatments.
  • To highlight the need for more rigorous clinical trials in pemphigus management.

Main Methods:

  • Review of available scientific literature on pemphigus treatments.
  • Analysis of data from existing clinical studies, including randomized controlled trials where available.

Related Experiment Videos

  • Assessment of treatment efficacy and safety profiles for pemphigus vulgaris and pemphigus foliaceus.

    • Main Results:

    • Advances in systemic corticosteroid therapy have reduced pemphigus mortality.
    • Treatment complications are now the primary drivers of morbidity and mortality.
    • Limited randomized controlled studies exist to definitively assess treatment effectiveness.

    Conclusions:

    • The primary goal in pemphigus management is achieving remission with minimal medication and side effects.
    • Current treatment options are expanding, but robust evidence is often lacking.
    • Further high-quality research is crucial for optimizing pemphigus patient outcomes.